Rhumbline Advisers grew its stake in shares of Global Blood Therapeutics, Inc. (NASDAQ:GBT) by 118.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 41,801 shares of the company’s stock after buying an additional 22,670 shares during the period. Rhumbline Advisers owned approximately 0.10% of Global Blood Therapeutics worth $1,143,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Morgan Stanley lifted its holdings in shares of Global Blood Therapeutics by 140.0% during the 1st quarter. Morgan Stanley now owns 334,872 shares of the company’s stock valued at $12,340,000 after purchasing an additional 195,323 shares in the last quarter. Creative Planning lifted its holdings in shares of Global Blood Therapeutics by 3,380.5% during the 2nd quarter. Creative Planning now owns 41,801 shares of the company’s stock valued at $1,143,000 after purchasing an additional 40,600 shares in the last quarter. MARSHALL WACE ASIA Ltd bought a new position in shares of Global Blood Therapeutics during the 1st quarter valued at about $694,000. Vanguard Group Inc. lifted its holdings in shares of Global Blood Therapeutics by 40.1% during the 1st quarter. Vanguard Group Inc. now owns 2,535,980 shares of the company’s stock valued at $93,451,000 after purchasing an additional 726,366 shares in the last quarter. Finally, Teachers Advisors LLC lifted its holdings in shares of Global Blood Therapeutics by 426.2% during the 1st quarter. Teachers Advisors LLC now owns 156,195 shares of the company’s stock valued at $5,756,000 after purchasing an additional 126,513 shares in the last quarter. Hedge funds and other institutional investors own 86.07% of the company’s stock.

Several research firms have recently weighed in on GBT. Needham & Company LLC began coverage on Global Blood Therapeutics in a report on Wednesday. They set a “buy” rating and a $51.00 price objective on the stock. Wedbush reiterated an “ourperform” rating and set a $73.00 price objective on shares of Global Blood Therapeutics in a report on Monday, September 18th. BidaskClub cut Global Blood Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, September 14th. Cowen and Company reiterated an “outperform” rating and set a $83.00 price objective on shares of Global Blood Therapeutics in a report on Monday, August 14th. Finally, J P Morgan Chase & Co reiterated an “overweight” rating and set a $46.00 price objective (up previously from $44.00) on shares of Global Blood Therapeutics in a report on Tuesday, August 8th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and twelve have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $49.84.

In other Global Blood Therapeutics news, insider Jung Choi sold 3,000 shares of the stock in a transaction that occurred on Friday, July 21st. The stock was sold at an average price of $30.00, for a total value of $90,000.00. Following the transaction, the insider now owns 143,255 shares in the company, valued at $4,297,650. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Deval L. Patrick sold 27,053 shares of the stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $29.69, for a total value of $803,203.57. Following the completion of the transaction, the director now owns 12,053 shares in the company, valued at approximately $357,853.57. The disclosure for this sale can be found here. In the last quarter, insiders sold 33,053 shares of company stock worth $983,204. Corporate insiders own 5.30% of the company’s stock.

Shares of Global Blood Therapeutics, Inc. (GBT) opened at 28.50 on Friday. The firm has a 50-day moving average price of $27.87 and a 200 day moving average price of $30.05. Global Blood Therapeutics, Inc. has a 1-year low of $13.35 and a 1-year high of $41.15. The company’s market cap is $1.24 billion.

Global Blood Therapeutics (NASDAQ:GBT) last announced its quarterly earnings results on Monday, August 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.61) by $0.06. During the same period in the prior year, the business posted ($0.58) earnings per share. On average, equities analysts anticipate that Global Blood Therapeutics, Inc. will post ($2.44) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Global Blood Therapeutics, Inc. (GBT) Holdings Boosted by Rhumbline Advisers” was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at https://www.dailypolitical.com/2017/09/24/global-blood-therapeutics-inc-gbt-holdings-boosted-by-rhumbline-advisers.html.

Global Blood Therapeutics Company Profile

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Want to see what other hedge funds are holding GBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global Blood Therapeutics, Inc. (NASDAQ:GBT).

Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.